Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...

Novo Nordisk (NVO-0.31%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market.. As Reuters reports today, an online weight loss company ...

The bundle will offer Novo Nordisk’s popular weight-loss drug at all its dosage strengths paired with a Hims & Hers membership providing "access to 24/7 care, ongoing clinical support, and ...

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight ...

Within Denmark, Novo Nordisk has created thousands of new jobs, "which is a lot in a small country," Krogsgaard said. "The risk here is that this is one sector," Wertheim told 60 Minutes Overtime.

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases.

Novo Nordisk's decision has been criticized by some patients with Type 1 diabetes who prefer Levemir over other long-acting "basal" insulins such as Sanofi's Lantus and Novo Nordisk's Tresiba.

Before Novo Nordisk acquired Dicerna Pharma, that company was a partner in the R&D of drugs for metabolic disorders. The relationship began in 2019, with Novo Nordisk committing $225 million in ...

Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.

The Lexington site, which also consists of 33 and 75 Hayden Ave., includes Dicerna Therapeutics, a Novo Nordisk subsidiary focused on RNA interference (RNAi) drug development.